Compare FNWD & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNWD | IVVD |
|---|---|---|
| Founded | 1994 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.1M | 219.9M |
| IPO Year | 1996 | 2021 |
| Metric | FNWD | IVVD |
|---|---|---|
| Price | $43.24 | $0.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $37.50 | $8.75 |
| AVG Volume (30 Days) | 8.3K | ★ 4.7M |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | ★ 79.02 |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $53,426,000.00 |
| Revenue This Year | $17.40 | $61.57 |
| Revenue Next Year | $5.44 | $41.42 |
| P/E Ratio | $42.26 | ★ N/A |
| Revenue Growth | N/A | ★ 110.47 |
| 52 Week Low | $30.05 | $0.53 |
| 52 Week High | $45.90 | $3.07 |
| Indicator | FNWD | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 56.99 |
| Support Level | $42.56 | $0.72 |
| Resistance Level | $44.22 | $1.02 |
| Average True Range (ATR) | 0.68 | 0.08 |
| MACD | -0.11 | 0.01 |
| Stochastic Oscillator | 68.00 | 65.12 |
Finward Bancorp is a bank holding company that engages in the provision of financial services. It offers products and services related to Personal Banking, Cash Management, Savings Account, ebanking, Wealth Management, and Insurance Services. It is engaged in the business of attracting deposits from the general public and the origination of loans, mostly upon the security of single-family residences and commercial real estate, construction loans, commercial business loans, and municipal loans. Geographically, the activities are carried out throughout the United States. The Company operates as a single reportable segment that derives its revenue mainly from the business of banking.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.